Syed Naqvi
Cardiovascular Disease · Houston, TXNPI 1386090231
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Novartis at 33.7% of the total. Reporting peaked in 2024 at $5,687 and has fallen 77.8% since, to $1,263 in 2025.
Across 119 payments — averaging $79.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Eli Lilly$1K
- Amgen$1K
- Heartflow, Inc.$1K
- Biosense Webster, Inc.$293
- Abbott$283
- plus $2K from 27 others
Across 81 payments — averaging $46,372 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.4M
- Vanda Pharmaceuticals Inc.$596K
- AstraZeneca$402K
- Amgen$222K
- Novartis$149K
- Alnylam Pharmaceuticals Inc.$23K
- plus $599 from 1 others
What the payments were for
- Consulting fees$2,61328%
- Travel & lodging$2,39825%
- Food & beverage$4,33046%
- Education$1271%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $3,195 |
| Eli Lilly | 14 | $1,442 |
| Amgen | 17 | $1,180 |
| Heartflow, Inc. | 9 | $1,102 |
| Biosense Webster, Inc. | 2 | $293 |
| Abbott | 3 | $283 |
| Sanofi-aventis U.S. LLC | 2 | $250 |
| Lilly USA, LLC | 6 | $234 |
| Novo Nordisk | 6 | $208 |
| AstraZeneca | 11 | $184 |
| Baxter Healthcare | 3 | $161 |
| Alnylam Pharmaceuticals Inc. | 3 | $137 |
| Philips North America LLC | 1 | $112 |
| Cvrx, Inc. | 1 | $93 |
| Tactile Systems Technology Inc | 1 | $84 |
| Medtronic | 3 | $70 |
| Ormco Corporation | 1 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $48 |
| Boehringer Ingelheim | 2 | $35 |
| Biotronik Inc. | 1 | $32 |
| Seagen Inc. | 2 | $31 |
| Epizyme, Inc. | 2 | $29 |
| Edwards Lifesciences | 1 | $27 |
| Abiomed | 1 | $24 |
| Cardiva Medical, Inc. | 1 | $23 |
| AMAG Pharmaceuticals, Inc. | 1 | $23 |
| United Therapeutics Corporation | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Lantheus Medical Imaging, Inc. | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Cleerly, Inc. | 1 | $13 |
| Inspire Medical Systems, Inc. | 1 | $13 |
| Kaneka Medical America LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEQVIO$1,556
- FFRct$941
- Carto 3$293
- DISEASE STATE$250
- AVEIR$147
- ENTRESTO$131
- ONPATTRO$123
- HeartMate 3 Left Ventricular Assist Device$113
- (9520) IGT Devices Undivided$112
- ZEPBOUND$112
How this compares
$9,466 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 119 | $110,616 |
| FarxigaDapagliflozin Propanediol | 136 | $99,208 |
| EntrestoSacubitril/Valsartan | 70 | $70,782 |
| WegovySemaglutide | 18 | $24,594 |
| OzempicSemaglutide | 22 | $22,054 |
| JardianceEmpagliflozin | 13 | $10,010 |
| XareltoRivaroxaban | 12 | $8,866 |
| CorlanorIvabradine Hcl | 12 | $5,798 |
| Amiodarone Hcl | 29 | $1,234 |
| Midodrine Hcl | 13 | $1,181 |
| Rosuvastatin Calcium | 151 | $1,157 |
| Ezetimibe | 42 | $895 |
| Flecainide Acetate | 15 | $755 |
| Atorvastatin Calcium | 91 | $677 |
| Losartan Potassium | 120 | $657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $184 | $99,208136 claims |
| NovartisEntresto | $3,195 | $70,78270 claims |
| Novo NordiskWegovy, Ozempic | $208 | $46,64840 claims |
| Boehringer IngelheimJardiance | $35 | $10,01013 claims |
| AmgenCorlanor | $1,180 | $5,79812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Biykem BozkurtHouston$606K
- Reynolds DelgadoHouston$471K
- Christie BallantyneHouston$413K
- Asif AliHouston$411K
- Sanjay ManiarHouston$263K
- Joggy GeorgeHouston$231K
- Jerry EstepHouston$226K
- Stephen LittleHouston$144K
- Akira NishikawaHouston$109K
- Andres MesaHouston$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.